Requires any sponsor of a clinical trial in this state, including but not limited to, a pharmaceutical drug manufacturer, pharmaceutical drug wholesaler, academic medical center, voluntary group, federal agency or health care provider, that applies for a state grant to conduct such clinical trial, to conspicuously post certain information about such clinical trial on the department's website.
Summary
Bill S01755 aims to amend the public health law in New York by establishing requirements for clinical trials that apply for state grant funding. Specifically, it mandates that sponsors of such clinical trials must publicly disclose detailed information about the trials on the Department of Health's website. This includes information about the trial's purpose, design, sponsors, and potential adverse effects, ensuring transparency and accountability in clinical research conducted within the state.
Impact
The bill will significantly impact state laws governing clinical trials by introducing new transparency requirements for sponsors seeking state funding. It will necessitate the posting of comprehensive information about clinical trials, which could enhance public awareness and trust in clinical research. This change may also affect how health care providers and pharmaceutical companies approach the funding and execution of clinical trials in New York.
Sentiment
The sentiment surrounding Bill S01755 appears to be generally supportive, as it promotes transparency in clinical trials, a critical aspect of public health and safety. However, there may be concerns from stakeholders about the administrative burden of compliance and the potential impact on the willingness of sponsors to conduct trials in New York due to increased scrutiny.
Contention
Notable points of contention may arise from pharmaceutical companies and health care providers regarding the extent of information that must be disclosed and the implications of publicizing potentially sensitive data. Some stakeholders may argue that excessive transparency could hinder the competitive edge of clinical trials or discourage investment in research within the state.
Same As
Requires any sponsor of a clinical trial in this state, including but not limited to, a pharmaceutical drug manufacturer, pharmaceutical drug wholesaler, academic medical center, voluntary group, federal agency or health care provider, that applies for a state grant to conduct such clinical trial, to conspicuously post certain information about such clinical trial on the department's website.
Requires any sponsor of a clinical trial in this state, including but not limited to, a pharmaceutical drug manufacturer, pharmaceutical drug wholesaler, academic medical center, voluntary group, federal agency or health care provider, that applies for a state grant to conduct such clinical trial, to conspicuously post certain information about such clinical trial on the department's website.
Requires any sponsor of a clinical trial in this state, including but not limited to, a pharmaceutical drug manufacturer, pharmaceutical drug wholesaler, academic medical center, voluntary group, federal agency or health care provider, that applies for a state grant to conduct such clinical trial, to conspicuously post certain information about such clinical trial on the department's website.
Designates third full week of May of each year as "Clinical Trials Awareness Week" and May 20 of each year as "Clinical Trials Volunteers Appreciation Day" in NJ.